Show more →
Show more →
Show more →
Show more →
References
- Summary of Product Characteristics Jakavi®, most up to date version at www.medicines.ie.
- Verstovsek S, et al. N Engl J Med. 2012;366:799-807.
- Harrison C, et al. N Engl J Med. 2012;366:787-789.
- Verstovsek S et al. Longterm treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017; 10(1): 55.
- Verstovsek S et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol. 2017; 10(1): 156.